Targeting the Oncogenic hEag1 Ion Channel: Developing Venom Peptide-Based Pharmacological Tools
The status, timeline and source of this project. A free account opens every field.
Source: EU Funding & Tenders Portal
The human ether à go-go 1 (hEag1) ion channel, also known as Kv10.1, is a voltage-gated potassium channel that is highly expressed in the brain but remains largely absent in other tissues under healthy conditions. However, during cancer development, hEag1 is significantly upregulated in various tumours, making it a potential biomarker and therapeutic target. Its role in cancer, particularly in bre
- Status
- Under Construction
- Sector
- Commercial
- Location
- Austria
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Targeting the Oncogenic hEag1 Ion Channel: Developing Venom Peptide-Based Pharmacological Tools
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ongoing |
Taiyo status | Under Construction |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | The human ether à go-go 1 (hEag1) ion channel, also known as Kv10.1, is a voltage-gated potassium channel that is highly expressed in the brain but remains largely absent in other tissues under healthy conditions. However, during cancer development, hEag1 is significantly upregulated in various tumours, making it a potential biomarker and therapeutic target. Its role in cancer, particularly in breast cancer, is still not well understood, which makes exploring hEag1 a critical focus of my research. In this project, I aim to discover and develop the first series of selective hEag1 ligands that can be used as pharmacological probes and therapeutic leads to investigate the channel's function in breast cancer. Building on preliminary data, I will utilize the rich pharmacological diversity found in animal venoms to identify novel peptide ligands that target hEag1. Through structure-activity relationship (SAR) studies and advanced medicinal chemistry, I plan to enhance the potency and selectivity of both newly discovered and existing ligands. These optimized compounds will enable me to explore the functional role of hEag1 in breast cancer progression and assess its therapeutic potential. By integrating peptide chemistry, pharmacology, and preclinical methodologies, this research will pave the way for the creation of highly specific hEag1-targeting probes and drugs. The ultimate goal is to deepen our understanding of hEag1's role in breast cancer and unlock new avenues for targeted cancer therapy, especially for aggressive forms like triple-negative breast cancer. |
Location
Country | Austria |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Commercial |
Article published date | 2026-01-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Commercial projects in Austria
- Drive-Through COVID-19 Community Testing
- Mellach CombinedCycle Gas Turbine CCGT Plant Austria
- Obervermuntwerk II Pumped Storage Power Plant Vorarlberg
- Break Stuff App
- Boehringer Ingelheim’s Biopharmaceutical Production Facility, Vienna, Austria
- HYPO VORARLBERG MEZZANINE ABS FOR EE & NZEB
- BITMOVIN (EGFF)
- AUSTRIAN ENERGY EFFICIENCY FL
